CAS: 15106-62-4; (S)-2-Amino-3-(3,5-Dichloro-4-Hydroxyphenyl)Propanoic Acid

相似化合物

1391508-43-2 7423-93-0 3387-87-9

上下游产品

CAS号60-18-4 L-酪氨酸 | CAS号205866-50-8 (S)-3-benzyloxy... | CAS号7782-50-5 氯气 | CAS号64-19-7 冰醋酸 | CAS号60-18-4 L-酪氨酸

📜L-酪氨酸置于n-氯代丁二酰亚胺,氯化亚砜,Potassium Carbonate体系中,用 四氢呋喃,甲醇,水 用作溶剂,化学反应 72.0H,反应生成3,5-二氯-L-酪氨酸
参考文献:氯-1-酪氨酸和溴-酪氨酸衍生物的合成及其锥虫活性
标题:氯-1-酪氨酸和溴-酪氨酸衍生物的合成及其锥虫活性
摘要:合成了二十二个卤化的1-酪氨酸衍生物,以研究用于治疗南美锥虫病的新物质.这些衍生物在甲基中具有甲基碘的不同取代度,可以合成伯,叔和季氨基酸.所有化合物均在体外针对克氏锥虫的胞内变形虫进行了测试,并通过单核细胞系u-937评估了细胞毒性.化合物25以75.52 µm的ec 50对抗克氏杆菌最具活性,而苯并硝唑的ec 50为58.79 µm的化合物最为有效.化合物3,4,7,和15种是具有最佳选择性指数(si)的值分别为7.5,8.3,12.1和8.6的衍生物.最后,化合物7是对抗t. Cruzi的更安全,更有前途的衍生物.
Doi:10.1007/s00044-018-2249-Y

专利信息

专利号:US-6013626-A
优先权日:1993-12-21
标题 :Cryptophycins from synthesis
发明人：MOORE RICHARD E; TIUS MARCUS A; BARROW RUSSELL A; LIANG JIAN; CORBETT THOMAS H; VALERIOTE FREDERICK A; GOLAKOTI TRIMURTULU; HEMSCHEIDT THOMAS K
权利人:UNIV HAWAII; UNIV WAYNE STATE
摘要:A cryptophycin compound is provided having the structure: ##STR1## Further provided are methods of producing cryptophycins by total synthesis and methods of using cryptophycins in pharmaceuticals. It is a further object of this invention to use cryptophycins to inhibit the proliferation of mammalian cells. Moreover, methods of using cryptophycins to treat neoplasia is also provided.

专利号:US-2023313245-A1
优先权日:2021-11-10
标 题 :Engineered Enzymes and Method for the Synthesis of Diverse Tyrosine Analogs

专利号:WO-2023086520-A2
优先权日:2021-11-10
标 题:Engineered enzymes and method for the synthesis of diverse tyrosine analogs

专利号:US-11230553-B2
优先权日:2016-05-09
标 题:Nannocystin process and products
发明人：WANG ZHANG; HUANG JUN
权利人:UNIV NEW YORK STATE RES FOUND
摘要:Described herein is a process for the total synthesis of macrolactones and macrolactams of formula Iincluding E- and Z-configuration thereof, in particular, nannocystins.

专利号:US-7034133-B2
优先权日:1997-09-12
标题 :Oligonucleotide analogues
发明人：WENGEL JESPER; NIELSEN POUL
权利人:EXIQON AS
摘要:Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a 'locked' structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.